Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07179055
Recruiting Phase 2

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055 · tracked via the Priya Life Science USA tracker
Sponsor
Vanda Pharmaceuticals
Phase
Phase 2
Started
2025-10
Last updated
2025-09-17

Condition(s) studied

Dry Eye

Investigational drug(s) / intervention(s)

VSJ-110Placebo

VSJ-110: ophthalmic solution

Placebo: ophthalmic solution

Study summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.

Primary outcome measure(s)

  • Corneal Staining — Measured over an 8-week treatment period
    Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.

Trial sites (5)

FacilityCityRegionStatus
Vanda Investigational Site Newport Beach California Recruiting
Vanda Investigational Site Andover Massachusetts Not Yet Recruiting
Vanda Investigational Site Shelby North Carolina Not Yet Recruiting
Vanda Investigational Site Memphis Tennessee Recruiting
Vanda Investigational Site Lynchburg Virginia Not Yet Recruiting

More Vanda Pharmaceuticals trials in the USA

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Recruiting
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Enrolling by invitation
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Recruiting

Other trials for the same condition

The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease Recruiting
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07179055 on ClinicalTrials.gov ↗ ← All trials in the USA